Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.6/3237 |
Resumo: | Retinoic acid (RA) plays an important role in the developing mammalian nervous system and has been highlighted as a therapeutic option for some neurodegenerative diseases due to its neuroprotective, anti-inflammatory and pro-neurogenic properties. However, RA presents undesirable properties like poor water solubility and short half-life. Therefore, nanoparticles (NPs) are an excellent alternative to control the undesired side effects and to ensure intracellular transport and controlled release of RA. Thus, the aim of this work was to evaluate the effects of RA-loaded NPs (RA+-NPs) in an in vivo mouse model of Parkinson’s disease (PD) using a MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxin, and to compare with effects of soluble RA. Interestingly, in adult mice, RA+-NPs significantly reduced the MPTP lesion by increasing the percentage of tyrosine hydroxylase positive (TH+) dopaminergic neurons in the SN to levels similar to control as well as increasing the intensity and area occupied by TH+ fibers in the striatum. This protective effect mediated by RA+-NPs was more robust than when compared with effect of soluble RA. These effects were accompanied by an increase in mRNA expression in SN and striatum of Nurr1 and Pitx3, both transcription factors involved in dopaminergic survival and specification. The same pattern of Pitx3 mRNA expression was found in the SN of old mice. In conclusion, RA+-NPs show a robust protective effect against dopaminergic injury when compared to soluble RA, suggesting that RA+-NPs could be a good strategy to boost brain repair in PD. |
id |
RCAP_3a78880a2ebab8a4b9a509a228cf7585 |
---|---|
oai_identifier_str |
oai:ubibliorum.ubi.pt:10400.6/3237 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's diseaseDoença de Parkinson - Ácido retinóicoNeurónios dopaminérgicosNeuroprotecção - NanopartículasNanopartículasRetinoic acid (RA) plays an important role in the developing mammalian nervous system and has been highlighted as a therapeutic option for some neurodegenerative diseases due to its neuroprotective, anti-inflammatory and pro-neurogenic properties. However, RA presents undesirable properties like poor water solubility and short half-life. Therefore, nanoparticles (NPs) are an excellent alternative to control the undesired side effects and to ensure intracellular transport and controlled release of RA. Thus, the aim of this work was to evaluate the effects of RA-loaded NPs (RA+-NPs) in an in vivo mouse model of Parkinson’s disease (PD) using a MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxin, and to compare with effects of soluble RA. Interestingly, in adult mice, RA+-NPs significantly reduced the MPTP lesion by increasing the percentage of tyrosine hydroxylase positive (TH+) dopaminergic neurons in the SN to levels similar to control as well as increasing the intensity and area occupied by TH+ fibers in the striatum. This protective effect mediated by RA+-NPs was more robust than when compared with effect of soluble RA. These effects were accompanied by an increase in mRNA expression in SN and striatum of Nurr1 and Pitx3, both transcription factors involved in dopaminergic survival and specification. The same pattern of Pitx3 mRNA expression was found in the SN of old mice. In conclusion, RA+-NPs show a robust protective effect against dopaminergic injury when compared to soluble RA, suggesting that RA+-NPs could be a good strategy to boost brain repair in PD.O ácido retinóico (AR) desempenha uma função importante no desenvolvimento do sistema nervoso dos mamíferos e tem sido evidenciado como uma opção terapêutica para diversas doenças neurodegenerativas devido às suas propriedades neuroprotetoras, anti-inflamatórias e pro-neurogénicas. Contudo, o AR apresenta propriedades indesejáveis, tais como: a fraca solubilidade em água e o curto tempo de semi-vida. Por este motivo, as nanopartículas (NPs) apresentam-se como uma excelente alternativa de modo a contornar essas propriedades indesejáveis garantindo o transporte intracelular e a libertação controlada de AR. O objectivo deste trabalho foi avaliar os efeitos da administração intracerebral (estriado) de NPs carregadas com AR (NPs + -AR) num modelo da doença de Parkinson (DP) em murganho utilizando a neurotoxina MPTP (1-metil-4-fenil-1,2,3,6-tetrahidropiridina), e a sua comparação com os efeitos da administração de AR solúvel. Curiosamente, em murganhos adultos observou-se que as NPs+ -AR reduziram significativamente a lesão provocada pelo MPTP, aumentando a percentagem de neurónios dopaminérgicos positivos para a tirosina hidroxilase (TH+ ) na substantia nigra (SN) para níveis similares ao controlo, bem como, a intensidade e área ocupada pelas fibras TH+ no estriado. Este efeito protetor mediado pelas NPs+ -AR foi mais robusto que o efeito proporcionado pelo AR solúvel. Estes efeitos foram acompanhados por um aumento da expressão na SN e estriado de RNAm de Nurr1 e Pitx3, ambos factores de transcrição envolvidos na especificação e sobrevivência neuronal dopaminérgica. O mesmo padrão de expressão de RNAm para Pitx3 foi detectado na SN de murganhos idosos. Em suma, as NPs+ -AR apresentam um efeito protetor robusto contra a lesão dopaminérgica quando comparadas com o AR solúvel, sugerindo que as NPs+ -AR podem ser uma boa estratégia para promover a reparação cerebral na DP.Bernardino, Liliana InácioBaltazar, Graça Maria FernandesuBibliorumEsteves, Marta Raquel Carrola2015-04-13T10:30:34Z2013-0620132013-06-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.6/3237enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-15T09:39:35Zoai:ubibliorum.ubi.pt:10400.6/3237Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:44:42.902475Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease |
title |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease |
spellingShingle |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease Esteves, Marta Raquel Carrola Doença de Parkinson - Ácido retinóico Neurónios dopaminérgicos Neuroprotecção - Nanopartículas Nanopartículas |
title_short |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease |
title_full |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease |
title_fullStr |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease |
title_full_unstemmed |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease |
title_sort |
Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model of Parkinson's disease |
author |
Esteves, Marta Raquel Carrola |
author_facet |
Esteves, Marta Raquel Carrola |
author_role |
author |
dc.contributor.none.fl_str_mv |
Bernardino, Liliana Inácio Baltazar, Graça Maria Fernandes uBibliorum |
dc.contributor.author.fl_str_mv |
Esteves, Marta Raquel Carrola |
dc.subject.por.fl_str_mv |
Doença de Parkinson - Ácido retinóico Neurónios dopaminérgicos Neuroprotecção - Nanopartículas Nanopartículas |
topic |
Doença de Parkinson - Ácido retinóico Neurónios dopaminérgicos Neuroprotecção - Nanopartículas Nanopartículas |
description |
Retinoic acid (RA) plays an important role in the developing mammalian nervous system and has been highlighted as a therapeutic option for some neurodegenerative diseases due to its neuroprotective, anti-inflammatory and pro-neurogenic properties. However, RA presents undesirable properties like poor water solubility and short half-life. Therefore, nanoparticles (NPs) are an excellent alternative to control the undesired side effects and to ensure intracellular transport and controlled release of RA. Thus, the aim of this work was to evaluate the effects of RA-loaded NPs (RA+-NPs) in an in vivo mouse model of Parkinson’s disease (PD) using a MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxin, and to compare with effects of soluble RA. Interestingly, in adult mice, RA+-NPs significantly reduced the MPTP lesion by increasing the percentage of tyrosine hydroxylase positive (TH+) dopaminergic neurons in the SN to levels similar to control as well as increasing the intensity and area occupied by TH+ fibers in the striatum. This protective effect mediated by RA+-NPs was more robust than when compared with effect of soluble RA. These effects were accompanied by an increase in mRNA expression in SN and striatum of Nurr1 and Pitx3, both transcription factors involved in dopaminergic survival and specification. The same pattern of Pitx3 mRNA expression was found in the SN of old mice. In conclusion, RA+-NPs show a robust protective effect against dopaminergic injury when compared to soluble RA, suggesting that RA+-NPs could be a good strategy to boost brain repair in PD. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-06 2013 2013-06-01T00:00:00Z 2015-04-13T10:30:34Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.6/3237 |
url |
http://hdl.handle.net/10400.6/3237 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799136344087199744 |